Download fulltext
HTML
1.
Mazloumi M, Dalvin LA, Abtahi S-H, Yavari N, Yaghy A, Mashayekhi A, Shields JA, Shields CL. Photodynamic Therapy in Ocular Oncology. JOVR [Internet]. 2020Oct.25 [cited 2024Apr.27];15(4):547–558. Available from: https://knepublishing.com/index.php/JOVR/article/view/7793
https://doi.org/10.18502/jovr.v15i4.7793
statistics
- 1263 Abstract Views
- 698 PDF Views
- 0 HTML Views
- Cited by 4 articles
authors
-
Mehdi Mazloumi
Mehdi Mazloumi
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, USA
-
Lauren A Dalvin
Lauren A Dalvin
Department of Ophthalmology, Mayo Clinic, Rochester, USA
-
Seyed-Hossein Abtahi
Seyed-Hossein Abtahi
Isfahan Eye Research Center, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
-
Negin Yavari
Negin Yavari
Department of Cardiovascular Research, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
-
Antonio Yaghy
Antonio Yaghy
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, USA
-
Arman Mashayekhi
Arman Mashayekhi
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, USA
-
Jerry A Shields
Jerry A Shields
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, USA
-
Carol L Shields
Carol L Shields
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, USA
Published Date
- Oct 25, 2020
Photodynamic Therapy in Ocular Oncology
Abstract
Over the past two decades, we have witnessed the increasing use of photodynamic therapy (PDT) in the field of ocular oncology. Based on a review of the literature and our own experience, we herein review the role of PDT for the management of intraocular tumors. The discussion includes two main topics. First, we discuss the application of PDT for benign tumors, including circumscribed choroidal hemangioma, choroidal osteoma, retinal astrocytoma, retinal capillary hemangioma (retinal hemangioblastoma), and retinal vasoproliferative tumor. Second, we assess the role of PDT for malignant tumors, including choroidal melanoma and choroidal metastasis.
Keywords:
Choroid, Eye, Hemangioma, Melanoma, Metastasis, Photodynamic therapy Retina, Tumor
References
1. Kwiatkowski S, Knap B, Przystupski D, Saczko J, Kedzierska E, Knap-Czop K, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother 2018;106:1098–1107.
2. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003;3:380–387.
3. Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic therapy for choroidal neovascularization: a review. Retina 2002;22:391–405.
4. Hata M, Tagawa M, Oishi A, Kawashima Y, Nakata I, Akagi- Kurashige Y, et al. Efficacy of photodynamic therapy for polypoidal choroidal vasculopathy associated with and without pachychoroid phenotypes. Ophthalmol Retina 2019;3:1016–1025.
5. Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S. Photodynamic therapy for central serous chorioretinopathy. Eye 2014;28:944–957.
6. Blasi MA, Pagliara MM, Lanza A, Sammarco MG, Caputo CG, Grimaldi G, et al. Photodynamic therapy in ocular oncology. Biomedicines 2018;6:17.
7. Mashayekhi A, Shields CL. Circumscribed choroidal hemangioma. Curr Opin Ophthalmol 2003;14:142–149.
8. Dalvin LA, Lim LS, Chang M, Udyaver S, Mazloumi M, Vichitvejpaisal P, et al. Circumscribed choroidal hemangioma: clinical features and outcomes by age category in 458 cases. Saudi J Ophthalmol 2019;33:219– 228.
9. Shields CL, Honavar SG, Shields JA, Cater J, Demirci H. Circumscribed choroidal hemangioma: clinical manifestations and factors predictive of visual outcome in 200 consecutive cases. Ophthalmology 2001;108:2237– 2248.
10. Shields JA, Shields CL, Materin MA, Marr BP, Demirci H, Mashayekhi A. Changing concepts in management of circumscribed choroidal hemangioma: the 2003 J. Howard Stokes Lecture, Part 1. Ophthal Surg Laser Imag 2004;35:383–394.
11. Shields JA. Photodynamic therapy for choroidal hemangioma. Graefes Arch Clin Exp Ophthalmol 2006;244:1071–1072.
12. Subira O, Brosa H, Lorenzo-Parra D, Arias-Barquet L, Catala-Mora J, Cobos E, et al. Choroidal haemangioma and photodynamic therapy. Anatomical and functional response of patients with choroidal hemangioma treated with photodynamic therapy. Arch Soc Esp Oftalmol 2017;92:257–264.
13. Elizalde J, Vasquez L, Iyo F, Abengoechea S. Photodynamic therapy in the management of circumscribed choroidal hemangioma. Can J Ophthalmol 2012;47:16–20.
14. Zhang Y, Liu W, Fang Y, Qian J, Xu G, Wang W, et al. Photodynamic therapy for symptomatic circumscribed macular choroidal hemangioma in Chinese patients. Am J Ophthalmol 2010;150:710–5.e1.
15. Blasi MA, Tiberti AC, Scupola A, Balestrazzi A, Colangelo E, Valente P, et al. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: fiveyear outcomes. Ophthalmology 2010;117:1630–1637.
16. Shields CL, Dalvin LA, Lim LS, Chang M, Udyaver S, Mazloumi M, et al. Circumscribed choroidal hemangioma: visual outcome in the pre-photodynamic therapy era versus photodynamic therapy era in 458 cases. Ophthalmol Retina 2020;4:100–110.
17. Ho YF, Chao A, Chen KJ, Chao AN, Wang NK, Liu L, et al. Clinical outcomes and predictors of response to photodynamic therapy in symptomatic circumscribed choroidal hemangioma: a retrospective case series. PLOS ONE 2018;13:e0197088.
18. Di Nicola M, Williams BK Jr, Srinivasan A, Al-Dahmash S, Mashayekhi A, Shields JA, et al. Photodynamic therapy (PDT) for Circumscribed choroidal hemangioma in 79 consecutive patients: comparative analysis of factors predictive of visual outcome. Ophthalmol Retina 2020;S2468–6530:30171–30178.
19. Lee JH, Lee CS, Lee SC. Efficacy of double dose photodynamic therapy for circumscribed choroidal hemangioma. Retina 2019;39:392–397.
20. Su ZA, Tang XJ, Zhang LX, Su XH. Comparison of outcomes between overlapping-spot and singlespot photodynamic therapy for circumscribed choroidal hemangioma. Int J Ophthalmol 2014;7:66–70.
21. Pilotto E, Urban F, Parrozzani R, Midena E. Standard versus bolus photodynamic therapy in circumscribed choroidal hemangioma: functional outcomes. Eur J Ophthalmol 2011;21:452–458.
22. Beardsley RM, McCannel CA, McCannel TA. Recurrent leakage after Visudyne photodynamic therapy for the treatment of circumscribed choroidal hemangioma. Ophthalmic Surg Laser Imag Retina 2013;44:248–251.
23. Alameddine RM, Mansour AM, Kahtani E. Review of choroidal osteomas. Middle East Afr J Ophthalmol 2014;21:244.
24. Shields CL, Shields JA, Augsburger JJ. Choroidal osteoma. Surv Ophthalmol 1988;33:17–27.
25. Shields CL, Sun H, Demirci H, Shields JA. Factors predictive of tumor growth, tumor decalcification, choroidal neovascularization, and visual outcome in 74 eyes with choroidal osteoma. Arch Ophthalmol 2005;123:1658–1666.
26. Shields CL, Perez B, Materin MA, Mehta S, Shields JA. Optical coherence tomography of choroidal osteoma in 22 cases: evidence for photoreceptor atrophy over the decalcified portion of the tumor. Ophthalmology 2007;114:e53–e58.
27. Shields CL, Materin MA, Mehta S, Foxman BT, Shields JA. Regression of extrafoveal choroidal osteoma following photodynamic therapy. Arch Ophthalmol 2008;126:135– 137.
28. Mazloumi M, Dalvin LA, Ancona-Lezama D, Mashayekhi A, Shields CL. Photodynamic therapy for extrafoveolar choroidal osteoma. Retina 2020;40:966–971.
29. Zimmer-Galler IE, Robertson DM. Long-term observation of retinal lesions in tuberous sclerosis. Am J Ophthalmol 1995;119:318–324.
30. Shields JA, Eagle Jr RC, Shields CL, Marr BP. Aggressive retinal astrocytomas in four patients with tuberous sclerosis complex. Trans Am Ophthalmol Soc 2004;102:139.
31. Shields CL, Materin MA, Marr BP, Krepostman J, Shields JA. Resolution of exudative retinal detachment from retinal astrocytoma following photodynamic therapy. Arch Ophthalmol 2008;126:273–274.
32. House RJ, Mashayekhi A, Shields JA, Shields CL. Total regression of acquired retinal astrocytoma using photodynamic therapy. Retin Cases Brief Rep 2016;10:41– 43.
33. Mashayekhi A, Shields CL, Shields JA. Transient increased exudation after photodynamic therapy of intraocular tumors. Middle East Afr J Ophthalmol 2013;20:83.
34. Eskelin S, Tommila P, Palosaari T, Kivelä T. Photodynamic therapy with verteporfin to induce regression of aggressive retinal astrocytomas. Acta Ophthalmol 2008;86:794–799.
35. Shields CL, Shields JA, Eagle RC Jr, Cangemi F. Progressive enlargement of acquired retinal astrocytoma in 2 cases. Ophthalmology 2004;111:363–368.
36. Vilaplana D, Castilla M, Poposki V, Alameda F, Shields CL. Acquired retinal astrocytoma managed with endoresection. Retina 2006;26:1081–1082.
37. Tuncer S, Cebeci Z. Dramatic regression of presumed acquired retinal astrocytoma with photodynamic therapy. Middle East Afr J Ophthalmol 2014;21:283–286.
38. Drummond SR, Kemp EG. Retinal astrocytoma managed by brachytherapy. Ophthalmology 2009;116:597-e1.
39. Bloom SM, Mahl CF. Photocoagulation for serous detachment of the macula secondary to retinal astrocytoma. Retina 1991;11:416–422.
40. Mennel S, Hausmann N, Meyer CH, Peter S. Photodynamic therapy for exudative hamartoma in tuberous sclerosis. Arch Ophthalmol 2006;124:597–599.
41. House RJ, Mashayekhi A, Shields JA, Shields CL. Total regression of acquired retinal astrocytoma using photodynamic therapy. Retin Cases Brief Rep 2016;10:41– 43.
42. Binderup MLM, Stendell AS, Galanakis M, Moller HU, Kiilgaard JF, Bisgaard ML. Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease. Br J Ophthalmol 2018;102:942– 947.
43. Singh AD, Nouri M, Shields CL, Shields JA, Smith AF. Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel-Lindau disease. Ophthalmology 2001;108:1907–1911.
44. Shields CL, Douglass A, Higgins T, Samara WA, Shields JA. Retinal hemangiomas: understanding clinical features, imaging, and therapies. Retina Today [Internet]. 2015:61– 67. Available from: https://retinatoday.com/articles/2015- july-aug/retinal-hemangiomas-understanding-clinicalfeatures- imaging-and-therapies.
45. Wiley HE, Krivosic V, Gaudric A, Gorin MB, Shields C, Shields J, et al. Management of retinal hemangioblastoma in von Hippel-Lindau disease. Retina 2019;39:2254–2263.
46. Singh AD, Nouri M, Shields CL, Shields JA, Perez N. Treatment of retinal capillary hemangioma. Ophthalmology 2002;109:1799–1806.
47. Sturzeneker G, Maia A, Morales M, Belfort R N. Vitreoretinal surgery and panretinal photocoagulation in a patient with multiple large retinal capillary hemangiomas (von Hippel-Lindau disease): a novel approach. Case Rep Ophthalmol 2019;10:327–333.
48. Wong WT, Liang KJ, Hammel K, Coleman HR, Chew EY. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease. Ophthalmology 2008;115:1957–1964.
49. Caminal JM, Maidana DE, Carnota P, Cobos-Martin E, Arias L. Retinal hemangioblastoma regression after single session of photodynamic therapy. JAMA Ophthalmol 2014;132:559.
50. Stattin M, Kralinger M, Haas G, Zehetner C, Bechrakis EN. Photodynamic therapy for retinal capillary hemangioblastoma. Can J Ophthalmol 2014;49:e32– e35.
51. Sachdeva R, Dadgostar H, Kaiser PK, Sears JE, Singh AD. Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol 2010;88:e334– e340.
52. Papastefanou VP, Pilli S, Stinghe A, Lotery AJ, Cohen VM. Photodynamic therapy for retinal capillary hemangioma. Eye 2013;27:438–442.
53. Shields JA, Decker WL, Sanborn GE, Augsburger JJ, Goldberg RE. Presumed acquired retinal hemangiomas. Ophthalmology 1983;90:1292–1300.
54. Shields CL, Shields JA, Barrett J, De Potter P. Vasoproliferative tumors of the ocular fundus: classification and clinical manifestations in 103 patients. Arch Ophthalmol 1995;113:615–623.
55. Shields CL, Kaliki S, Al-Dahmash S, Rojanaporn D, Shukla SY, Reilly B, et al. Retinal vasoproliferative tumors: comparative clinical features of primary vs secondary tumors in 334 cases. JAMA Ophthalmol 2013;131:328– 334.
56. Barbezetto IA, Smith RT. Vasoproliferative tumor of the retina treated with PDT. Retina 2003;23:565–567.
57. Gottlieb F, Fammartino JJ, Stratford TP, Brockhurst RJ. Retinal angiomatous mass. A complication of retinal detachment surgery. Retina 1984;4:152–157.
58. Honavar SG. Retinal vasoproliferative tumor - a proposal for classification. Indian J Ophthalmol 2018;66:185–186.
59. Krivosic V, Massin P, Desjardins L, Le Hoang P, Tadayoni R, Gaudric A. Management of idiopathic retinal vasoproliferative tumors by slit-lamp laser or endolaser photocoagulation. Am J Ophthalmol 2014;158:154–161.e1.
60. Nickerson SJ, Al-Dahmash SA, Shields CL, Shields JA. Retinal vasoproliferative tumor with total retinal detachment managed with plaque radiotherapy. Oman J Ophthalmol 2012;5:53–54.
61. Saito W, Kase S, Fujiya A, Dong Z, Noda K, Ishida S. Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors. Retina 2013;33:1959– 1967.
62. Rogers C, Damato B, Kumar I, Heimann H. Intravitreal bevacizumab in the treatment of vasoproliferative retinal tumours. Eye 2014;28:968–973.
63. Osman SA, Aylin Y, Gul A, Celikel H. Photodynamic treatment of a secondary vasoproliferative tumour associated with sector retinitis pigmentosa and Usher syndrome type I. Clin Exp Ophthalmol 2007;35:191–193.
64. Hussain RN, Jmor F, Damato B, Heimann H. Verteporfin photodynamic therapy for the treatment of retinal vasoproliferative tumors. Ophthalmology 2015;122:2361– 2363.
65. Blasi MA, Scupola A, Tiberti AC, Sasso P, Balestrazzi E. Photodynamic therapy for vasoproliferative retinal tumors. Retina 2006;26:404–409.
66. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988;32:239–251.
67. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye 2017;31:241–257.
68. Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers 2020;6:24.
69. Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol 2018;30:102–109.
70. Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina 2012;32:1363–1372.
71. Vichitvejpaisal P, Dalvin LA, Mazloumi M, Ewens KG, Ganguly A, Shields CL. Genetic analysis of uveal melanoma in 658 patients using the cancer genome atlas classification of uveal melanoma as A, B, C, and D. Ophthalmology 2019;126:1445–1453.
72. Mazloumi M, Vichitvejpaisal P, Dalvin LA, Yaghy A, Ewens KG, Ganguly A, et al. Accuracy of The Cancer Genome Atlas Classification vs American Joint Committee on Cancer Classification for Prediction of Metastasis in Patients With Uveal Melanoma. JAMA Ophthalmol 2020;138:260–267.
73. Gamel J, McCurdy JB, McLean I. A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci 1992;33:1919–1922.
74. Turkoglu EB, Pointdujour-Lim R, Mashayekhi A, Shields CL. Photodynamic therapy as primary treatment for small choroidal melanoma. Retina 2019;39:1319–1325.
75. Shields CL, Shields JA, Perez N, Singh AD, Cater J. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology 2002;109:225–234.
76. Mashayekhi A, Shields CL, Rishi P, Atalay HT, Pellegrini M, McLaughlin JP, et al. Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control. Ophthalmology 2015;122:600– 609.
77. Lumbroso-Le Rouic L, Chefchaouni MC, Levy C, Plancher C, Dendale R, Asselain B, et al. 125 I plaque brachytherapy for anterior uveal melanomas. Eye 2004;18:911–916.
78. Shields JA, Glazer LC, Mieler WF, Shields CL, Gottlieb MS. Comparison of xenon arc and argon laser photocoagulation in the treatment of choroidal melanomas. Am J Ophthalmol 1990;109:647–655.
79. Oosterhuis JA, Journée-de Korver HG, Keunen JE. Transpupillary thermotherapy: results in 50 patients with choroidal melanoma. Arch Ophthalmol 1998;116:157–162.
80. Campbell WG, Pejnovic TM. Treatment of amelanotic choroidal melanoma with photodynamic therapy. Retina 2012;32:1356–1362.
81. Barbazetto IA, Lee TC, Rollins IS, Chang S, Abramson DH. Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol 2003;135:898–899.
82. Fabian ID, Stacey AW, Papastefanou V, Al Harby L, Arora AK, Sagoo MS, et al. Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma. Eye 2017;31:519–528.
83. Rundle P. Treatment of posterior uveal melanoma with multi-dose photodynamic therapy. Br J Ophthalmol 2014;98:494–497.
84. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994;101:1953–1961.
85. Blasi MA, Laguardia M, Tagliaferri L, Scupola A, Villano A, Caputo CG, et al. Brachytherapy alone or with neoadjuvant photodynamic therapy for amelanotic choroidal melanoma: Functional outcomes and local tumor control. Retina 2016;36:2205–2212.
86. Tuncer S, Kir N, Shields CL. Dramatic regression of amelanotic choroidal melanoma with PDT following poor response to brachytherapy. Ophthalmic Surg Laser Imag 2012;43:e38–e40.
87. Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE. Survey of 520 eyes with uveal metastases. Ophthalmology 1997;104:1265–1276.
88. Arepalli S, Kaliki S, Shields CL. Choroidal metastases: origin, features, and therapy. Indian J Ophthalmol 2015;63:122.
89. Shields CL, Welch RJ, Malik K, Acaba-Berrocal LA, Selzer EB, Newman JH, et al. Uveal metastasis: clinical features and survival outcome of 2214 tumors in 1111 patients based on primary tumor origin. Middle East Afr J Ophthalmol 2018;25:81–90.
90. Shields CL, Khoo CT, Mazloumi M, Mashayekhi A, Shields JA. Photodynamic therapy for choroidal metastasis: Tumor control and visual outcome in 58 cases. The 2019 Burnier International Ocular Pathology Society (BIOPSY) Lecture. Ophthalmol Retina 2019;4:310–319.
91. Kaliki S, Shields CL, Al-Dahmash SA, Mashayekhi A, Shields JA. Photodynamic therapy for choroidal metastasis in 8 cases. Ophthalmology 2012;119:1218– 1222.
92. Ghodasra DH, Demirci H. Photodynamic therapy for choroidal metastasis. Am J Ophthalmol 2016;161:104– 9.e2.
2. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003;3:380–387.
3. Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic therapy for choroidal neovascularization: a review. Retina 2002;22:391–405.
4. Hata M, Tagawa M, Oishi A, Kawashima Y, Nakata I, Akagi- Kurashige Y, et al. Efficacy of photodynamic therapy for polypoidal choroidal vasculopathy associated with and without pachychoroid phenotypes. Ophthalmol Retina 2019;3:1016–1025.
5. Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S. Photodynamic therapy for central serous chorioretinopathy. Eye 2014;28:944–957.
6. Blasi MA, Pagliara MM, Lanza A, Sammarco MG, Caputo CG, Grimaldi G, et al. Photodynamic therapy in ocular oncology. Biomedicines 2018;6:17.
7. Mashayekhi A, Shields CL. Circumscribed choroidal hemangioma. Curr Opin Ophthalmol 2003;14:142–149.
8. Dalvin LA, Lim LS, Chang M, Udyaver S, Mazloumi M, Vichitvejpaisal P, et al. Circumscribed choroidal hemangioma: clinical features and outcomes by age category in 458 cases. Saudi J Ophthalmol 2019;33:219– 228.
9. Shields CL, Honavar SG, Shields JA, Cater J, Demirci H. Circumscribed choroidal hemangioma: clinical manifestations and factors predictive of visual outcome in 200 consecutive cases. Ophthalmology 2001;108:2237– 2248.
10. Shields JA, Shields CL, Materin MA, Marr BP, Demirci H, Mashayekhi A. Changing concepts in management of circumscribed choroidal hemangioma: the 2003 J. Howard Stokes Lecture, Part 1. Ophthal Surg Laser Imag 2004;35:383–394.
11. Shields JA. Photodynamic therapy for choroidal hemangioma. Graefes Arch Clin Exp Ophthalmol 2006;244:1071–1072.
12. Subira O, Brosa H, Lorenzo-Parra D, Arias-Barquet L, Catala-Mora J, Cobos E, et al. Choroidal haemangioma and photodynamic therapy. Anatomical and functional response of patients with choroidal hemangioma treated with photodynamic therapy. Arch Soc Esp Oftalmol 2017;92:257–264.
13. Elizalde J, Vasquez L, Iyo F, Abengoechea S. Photodynamic therapy in the management of circumscribed choroidal hemangioma. Can J Ophthalmol 2012;47:16–20.
14. Zhang Y, Liu W, Fang Y, Qian J, Xu G, Wang W, et al. Photodynamic therapy for symptomatic circumscribed macular choroidal hemangioma in Chinese patients. Am J Ophthalmol 2010;150:710–5.e1.
15. Blasi MA, Tiberti AC, Scupola A, Balestrazzi A, Colangelo E, Valente P, et al. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: fiveyear outcomes. Ophthalmology 2010;117:1630–1637.
16. Shields CL, Dalvin LA, Lim LS, Chang M, Udyaver S, Mazloumi M, et al. Circumscribed choroidal hemangioma: visual outcome in the pre-photodynamic therapy era versus photodynamic therapy era in 458 cases. Ophthalmol Retina 2020;4:100–110.
17. Ho YF, Chao A, Chen KJ, Chao AN, Wang NK, Liu L, et al. Clinical outcomes and predictors of response to photodynamic therapy in symptomatic circumscribed choroidal hemangioma: a retrospective case series. PLOS ONE 2018;13:e0197088.
18. Di Nicola M, Williams BK Jr, Srinivasan A, Al-Dahmash S, Mashayekhi A, Shields JA, et al. Photodynamic therapy (PDT) for Circumscribed choroidal hemangioma in 79 consecutive patients: comparative analysis of factors predictive of visual outcome. Ophthalmol Retina 2020;S2468–6530:30171–30178.
19. Lee JH, Lee CS, Lee SC. Efficacy of double dose photodynamic therapy for circumscribed choroidal hemangioma. Retina 2019;39:392–397.
20. Su ZA, Tang XJ, Zhang LX, Su XH. Comparison of outcomes between overlapping-spot and singlespot photodynamic therapy for circumscribed choroidal hemangioma. Int J Ophthalmol 2014;7:66–70.
21. Pilotto E, Urban F, Parrozzani R, Midena E. Standard versus bolus photodynamic therapy in circumscribed choroidal hemangioma: functional outcomes. Eur J Ophthalmol 2011;21:452–458.
22. Beardsley RM, McCannel CA, McCannel TA. Recurrent leakage after Visudyne photodynamic therapy for the treatment of circumscribed choroidal hemangioma. Ophthalmic Surg Laser Imag Retina 2013;44:248–251.
23. Alameddine RM, Mansour AM, Kahtani E. Review of choroidal osteomas. Middle East Afr J Ophthalmol 2014;21:244.
24. Shields CL, Shields JA, Augsburger JJ. Choroidal osteoma. Surv Ophthalmol 1988;33:17–27.
25. Shields CL, Sun H, Demirci H, Shields JA. Factors predictive of tumor growth, tumor decalcification, choroidal neovascularization, and visual outcome in 74 eyes with choroidal osteoma. Arch Ophthalmol 2005;123:1658–1666.
26. Shields CL, Perez B, Materin MA, Mehta S, Shields JA. Optical coherence tomography of choroidal osteoma in 22 cases: evidence for photoreceptor atrophy over the decalcified portion of the tumor. Ophthalmology 2007;114:e53–e58.
27. Shields CL, Materin MA, Mehta S, Foxman BT, Shields JA. Regression of extrafoveal choroidal osteoma following photodynamic therapy. Arch Ophthalmol 2008;126:135– 137.
28. Mazloumi M, Dalvin LA, Ancona-Lezama D, Mashayekhi A, Shields CL. Photodynamic therapy for extrafoveolar choroidal osteoma. Retina 2020;40:966–971.
29. Zimmer-Galler IE, Robertson DM. Long-term observation of retinal lesions in tuberous sclerosis. Am J Ophthalmol 1995;119:318–324.
30. Shields JA, Eagle Jr RC, Shields CL, Marr BP. Aggressive retinal astrocytomas in four patients with tuberous sclerosis complex. Trans Am Ophthalmol Soc 2004;102:139.
31. Shields CL, Materin MA, Marr BP, Krepostman J, Shields JA. Resolution of exudative retinal detachment from retinal astrocytoma following photodynamic therapy. Arch Ophthalmol 2008;126:273–274.
32. House RJ, Mashayekhi A, Shields JA, Shields CL. Total regression of acquired retinal astrocytoma using photodynamic therapy. Retin Cases Brief Rep 2016;10:41– 43.
33. Mashayekhi A, Shields CL, Shields JA. Transient increased exudation after photodynamic therapy of intraocular tumors. Middle East Afr J Ophthalmol 2013;20:83.
34. Eskelin S, Tommila P, Palosaari T, Kivelä T. Photodynamic therapy with verteporfin to induce regression of aggressive retinal astrocytomas. Acta Ophthalmol 2008;86:794–799.
35. Shields CL, Shields JA, Eagle RC Jr, Cangemi F. Progressive enlargement of acquired retinal astrocytoma in 2 cases. Ophthalmology 2004;111:363–368.
36. Vilaplana D, Castilla M, Poposki V, Alameda F, Shields CL. Acquired retinal astrocytoma managed with endoresection. Retina 2006;26:1081–1082.
37. Tuncer S, Cebeci Z. Dramatic regression of presumed acquired retinal astrocytoma with photodynamic therapy. Middle East Afr J Ophthalmol 2014;21:283–286.
38. Drummond SR, Kemp EG. Retinal astrocytoma managed by brachytherapy. Ophthalmology 2009;116:597-e1.
39. Bloom SM, Mahl CF. Photocoagulation for serous detachment of the macula secondary to retinal astrocytoma. Retina 1991;11:416–422.
40. Mennel S, Hausmann N, Meyer CH, Peter S. Photodynamic therapy for exudative hamartoma in tuberous sclerosis. Arch Ophthalmol 2006;124:597–599.
41. House RJ, Mashayekhi A, Shields JA, Shields CL. Total regression of acquired retinal astrocytoma using photodynamic therapy. Retin Cases Brief Rep 2016;10:41– 43.
42. Binderup MLM, Stendell AS, Galanakis M, Moller HU, Kiilgaard JF, Bisgaard ML. Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease. Br J Ophthalmol 2018;102:942– 947.
43. Singh AD, Nouri M, Shields CL, Shields JA, Smith AF. Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel-Lindau disease. Ophthalmology 2001;108:1907–1911.
44. Shields CL, Douglass A, Higgins T, Samara WA, Shields JA. Retinal hemangiomas: understanding clinical features, imaging, and therapies. Retina Today [Internet]. 2015:61– 67. Available from: https://retinatoday.com/articles/2015- july-aug/retinal-hemangiomas-understanding-clinicalfeatures- imaging-and-therapies.
45. Wiley HE, Krivosic V, Gaudric A, Gorin MB, Shields C, Shields J, et al. Management of retinal hemangioblastoma in von Hippel-Lindau disease. Retina 2019;39:2254–2263.
46. Singh AD, Nouri M, Shields CL, Shields JA, Perez N. Treatment of retinal capillary hemangioma. Ophthalmology 2002;109:1799–1806.
47. Sturzeneker G, Maia A, Morales M, Belfort R N. Vitreoretinal surgery and panretinal photocoagulation in a patient with multiple large retinal capillary hemangiomas (von Hippel-Lindau disease): a novel approach. Case Rep Ophthalmol 2019;10:327–333.
48. Wong WT, Liang KJ, Hammel K, Coleman HR, Chew EY. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease. Ophthalmology 2008;115:1957–1964.
49. Caminal JM, Maidana DE, Carnota P, Cobos-Martin E, Arias L. Retinal hemangioblastoma regression after single session of photodynamic therapy. JAMA Ophthalmol 2014;132:559.
50. Stattin M, Kralinger M, Haas G, Zehetner C, Bechrakis EN. Photodynamic therapy for retinal capillary hemangioblastoma. Can J Ophthalmol 2014;49:e32– e35.
51. Sachdeva R, Dadgostar H, Kaiser PK, Sears JE, Singh AD. Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol 2010;88:e334– e340.
52. Papastefanou VP, Pilli S, Stinghe A, Lotery AJ, Cohen VM. Photodynamic therapy for retinal capillary hemangioma. Eye 2013;27:438–442.
53. Shields JA, Decker WL, Sanborn GE, Augsburger JJ, Goldberg RE. Presumed acquired retinal hemangiomas. Ophthalmology 1983;90:1292–1300.
54. Shields CL, Shields JA, Barrett J, De Potter P. Vasoproliferative tumors of the ocular fundus: classification and clinical manifestations in 103 patients. Arch Ophthalmol 1995;113:615–623.
55. Shields CL, Kaliki S, Al-Dahmash S, Rojanaporn D, Shukla SY, Reilly B, et al. Retinal vasoproliferative tumors: comparative clinical features of primary vs secondary tumors in 334 cases. JAMA Ophthalmol 2013;131:328– 334.
56. Barbezetto IA, Smith RT. Vasoproliferative tumor of the retina treated with PDT. Retina 2003;23:565–567.
57. Gottlieb F, Fammartino JJ, Stratford TP, Brockhurst RJ. Retinal angiomatous mass. A complication of retinal detachment surgery. Retina 1984;4:152–157.
58. Honavar SG. Retinal vasoproliferative tumor - a proposal for classification. Indian J Ophthalmol 2018;66:185–186.
59. Krivosic V, Massin P, Desjardins L, Le Hoang P, Tadayoni R, Gaudric A. Management of idiopathic retinal vasoproliferative tumors by slit-lamp laser or endolaser photocoagulation. Am J Ophthalmol 2014;158:154–161.e1.
60. Nickerson SJ, Al-Dahmash SA, Shields CL, Shields JA. Retinal vasoproliferative tumor with total retinal detachment managed with plaque radiotherapy. Oman J Ophthalmol 2012;5:53–54.
61. Saito W, Kase S, Fujiya A, Dong Z, Noda K, Ishida S. Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors. Retina 2013;33:1959– 1967.
62. Rogers C, Damato B, Kumar I, Heimann H. Intravitreal bevacizumab in the treatment of vasoproliferative retinal tumours. Eye 2014;28:968–973.
63. Osman SA, Aylin Y, Gul A, Celikel H. Photodynamic treatment of a secondary vasoproliferative tumour associated with sector retinitis pigmentosa and Usher syndrome type I. Clin Exp Ophthalmol 2007;35:191–193.
64. Hussain RN, Jmor F, Damato B, Heimann H. Verteporfin photodynamic therapy for the treatment of retinal vasoproliferative tumors. Ophthalmology 2015;122:2361– 2363.
65. Blasi MA, Scupola A, Tiberti AC, Sasso P, Balestrazzi E. Photodynamic therapy for vasoproliferative retinal tumors. Retina 2006;26:404–409.
66. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988;32:239–251.
67. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye 2017;31:241–257.
68. Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers 2020;6:24.
69. Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol 2018;30:102–109.
70. Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina 2012;32:1363–1372.
71. Vichitvejpaisal P, Dalvin LA, Mazloumi M, Ewens KG, Ganguly A, Shields CL. Genetic analysis of uveal melanoma in 658 patients using the cancer genome atlas classification of uveal melanoma as A, B, C, and D. Ophthalmology 2019;126:1445–1453.
72. Mazloumi M, Vichitvejpaisal P, Dalvin LA, Yaghy A, Ewens KG, Ganguly A, et al. Accuracy of The Cancer Genome Atlas Classification vs American Joint Committee on Cancer Classification for Prediction of Metastasis in Patients With Uveal Melanoma. JAMA Ophthalmol 2020;138:260–267.
73. Gamel J, McCurdy JB, McLean I. A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci 1992;33:1919–1922.
74. Turkoglu EB, Pointdujour-Lim R, Mashayekhi A, Shields CL. Photodynamic therapy as primary treatment for small choroidal melanoma. Retina 2019;39:1319–1325.
75. Shields CL, Shields JA, Perez N, Singh AD, Cater J. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology 2002;109:225–234.
76. Mashayekhi A, Shields CL, Rishi P, Atalay HT, Pellegrini M, McLaughlin JP, et al. Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control. Ophthalmology 2015;122:600– 609.
77. Lumbroso-Le Rouic L, Chefchaouni MC, Levy C, Plancher C, Dendale R, Asselain B, et al. 125 I plaque brachytherapy for anterior uveal melanomas. Eye 2004;18:911–916.
78. Shields JA, Glazer LC, Mieler WF, Shields CL, Gottlieb MS. Comparison of xenon arc and argon laser photocoagulation in the treatment of choroidal melanomas. Am J Ophthalmol 1990;109:647–655.
79. Oosterhuis JA, Journée-de Korver HG, Keunen JE. Transpupillary thermotherapy: results in 50 patients with choroidal melanoma. Arch Ophthalmol 1998;116:157–162.
80. Campbell WG, Pejnovic TM. Treatment of amelanotic choroidal melanoma with photodynamic therapy. Retina 2012;32:1356–1362.
81. Barbazetto IA, Lee TC, Rollins IS, Chang S, Abramson DH. Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol 2003;135:898–899.
82. Fabian ID, Stacey AW, Papastefanou V, Al Harby L, Arora AK, Sagoo MS, et al. Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma. Eye 2017;31:519–528.
83. Rundle P. Treatment of posterior uveal melanoma with multi-dose photodynamic therapy. Br J Ophthalmol 2014;98:494–497.
84. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994;101:1953–1961.
85. Blasi MA, Laguardia M, Tagliaferri L, Scupola A, Villano A, Caputo CG, et al. Brachytherapy alone or with neoadjuvant photodynamic therapy for amelanotic choroidal melanoma: Functional outcomes and local tumor control. Retina 2016;36:2205–2212.
86. Tuncer S, Kir N, Shields CL. Dramatic regression of amelanotic choroidal melanoma with PDT following poor response to brachytherapy. Ophthalmic Surg Laser Imag 2012;43:e38–e40.
87. Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE. Survey of 520 eyes with uveal metastases. Ophthalmology 1997;104:1265–1276.
88. Arepalli S, Kaliki S, Shields CL. Choroidal metastases: origin, features, and therapy. Indian J Ophthalmol 2015;63:122.
89. Shields CL, Welch RJ, Malik K, Acaba-Berrocal LA, Selzer EB, Newman JH, et al. Uveal metastasis: clinical features and survival outcome of 2214 tumors in 1111 patients based on primary tumor origin. Middle East Afr J Ophthalmol 2018;25:81–90.
90. Shields CL, Khoo CT, Mazloumi M, Mashayekhi A, Shields JA. Photodynamic therapy for choroidal metastasis: Tumor control and visual outcome in 58 cases. The 2019 Burnier International Ocular Pathology Society (BIOPSY) Lecture. Ophthalmol Retina 2019;4:310–319.
91. Kaliki S, Shields CL, Al-Dahmash SA, Mashayekhi A, Shields JA. Photodynamic therapy for choroidal metastasis in 8 cases. Ophthalmology 2012;119:1218– 1222.
92. Ghodasra DH, Demirci H. Photodynamic therapy for choroidal metastasis. Am J Ophthalmol 2016;161:104– 9.e2.